Related references
Note: Only part of the references are listed.β-fetoprotein and human chorionic gonadotrophin-β as prognostic markers in neuroendocrine tumour patients
T. Shah et al.
BRITISH JOURNAL OF CANCER (2008)
Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors
Ulrich-Frank Pape et al.
CANCER (2008)
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours
Ulrich-Frank Pape et al.
ENDOCRINE-RELATED CANCER (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
Sara Ekeblad et al.
CLINICAL CANCER RESEARCH (2007)
Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours
Christos Toumpanakis et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
Eduardo Vilar et al.
ENDOCRINE-RELATED CANCER (2007)
TNM staging of foregut (neuro)endocrine tumors:: a consensus proposal including a grading system
G. Rindi et al.
VIRCHOWS ARCHIV (2006)
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
MH Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281
WJ Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II trial of gemcitabine for metastatic neuroendocrine tumors
MH Kulke et al.
CANCER (2004)
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas
MA Kouvaraki et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
